Effects of dapagliflozin on cardiovascular risk factors.
about
Diabetes DyslipidemiaPatient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XRSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsA comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesCardiovascular safety profile of currently available diabetic drugs.Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsShort commentary on empagliflozin and its potential clinical impactEnergy Balance After Sodium-Glucose Cotransporter 2 Inhibition.The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusDapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III StudiesQuality measure attainment with dapagliflozin plus metformin extended-release as initial combination therapy in patients with type 2 diabetes: a post hoc pooled analysis of two clinical studiesDapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol).Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.Combination therapy when metformin is not an option for type 2 diabetes.Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.SGLT2 Inhibitors: Benefit/Risk Balance.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.A Review of the Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis.No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis.Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
P2860
Q26750905-B0ABA439-1DF2-4825-906F-B0286B071FFAQ26766404-AA0C778F-7520-4F2F-9EC0-BA375549F9D7Q28072765-2F4230A0-2057-412C-ADF2-E63B325BC255Q33560279-11CE90C0-6625-403A-A72C-88CF054DDEFEQ33625568-8FD6CB22-75D8-4536-B4FD-39D1F8716B79Q33845734-0C8DFD04-C8AB-4A84-BB47-31176ADD55EAQ34161881-3D36874C-344E-4E5B-A71B-E5E2CF7BD271Q34198692-4C55DBBA-D6E0-4E82-8BF1-4366706260F3Q34971736-D4ACBDF7-BF0E-41A1-99F6-9CFF4F12BEFCQ34973750-F27B2B73-59E3-4887-BC9D-17779420A9E5Q35528797-D1A15F86-E63A-4D17-915E-9C67ACC30BC8Q35973288-CAAA19B2-0B8C-45F3-84D1-14E6B5EFDF88Q36592820-CCCE1C9D-EAE8-4FDC-82C9-E985EC7354E3Q36851156-0110B34A-7824-4B12-B01F-2D45BF082CD9Q37075620-C8CB6D95-A613-4A03-BF6C-3EF4FE171D94Q37354187-A93B022D-061A-4BF2-8A85-82D0D01922C5Q37586607-B178AD9F-5640-4B76-8104-A55EDEB6375FQ37737454-B703EF95-A4F2-418C-B3D2-ADDAE29E13EFQ38211597-ABA4E61E-CDEB-46D6-AD89-CAC006BD7B63Q38260353-2D8F6570-D6B4-4AC8-8064-EE4ABABA7106Q38377267-ADEC5BA8-E95E-4FFA-9631-0C09DF44E349Q38524435-2F478EBE-4617-4E60-8A20-79D577B6B6D2Q38619164-A08BF378-0DE1-487E-A3E3-0DBE96470BC3Q38783203-B3D0D0E7-8DED-4CC2-9AB9-623B70CF6B59Q38821464-78888265-AB4F-4CBE-8F53-18BC0A21BE1DQ38827756-FE17D053-B65E-4A49-9DC0-3E009337C109Q38906041-8AABF1C4-C3E5-4E54-9A25-413EE57C7A23Q38931842-FFC30A9F-FAAC-46DA-84E2-959B9A6CFA42Q39170860-AA4FB12F-977A-4DE9-A3E7-778654EDB8F4Q39255188-B9B775AC-E81C-4921-B118-D46762E3ABA5Q39290337-B1F06BCA-C608-49E3-BE70-10D2B8CDA8D8Q39355218-530FE013-8FDD-49E4-BDAE-5E98D97375C2Q48189020-E8AFFC0E-C321-4ECA-99C0-A45FF9A28C94Q49689988-C929B3D4-1E74-4373-A392-E33A4092598BQ50027868-3295956B-5596-418D-9C66-A40BB995575BQ51034590-935738E7-0B5A-4346-9FB9-92CF5847F3C6Q55411384-041BC3AF-933A-4BD9-B2F8-01F81CBFFD19Q58456988-B2455015-EC96-4554-B4CB-B170EE5C3594
P2860
Effects of dapagliflozin on cardiovascular risk factors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Effects of dapagliflozin on cardiovascular risk factors.
@en
type
label
Effects of dapagliflozin on cardiovascular risk factors.
@en
prefLabel
Effects of dapagliflozin on cardiovascular risk factors.
@en
P2093
P2860
P356
P1476
Effects of dapagliflozin on cardiovascular risk factors.
@en
P2093
Agata Ptaszynska
Elise Hardy
Eva Johnsson
James List
Shamik Parikh
P2860
P304
P356
10.3810/PGM.2013.05.2667
P407
P577
2013-05-01T00:00:00Z